Business, energy, technology, markets and global industry news from Business News Today

central nervous system therapeutics

PharmaDeviceNews central nervous system therapeutics
Pharma & Biotech

Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?

Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.

Read More
Pharma & Biotech

Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia

Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.

Read More
Pharma & Biotech

Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program

Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.

Read More